Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies
Authors:
- 1 January 2013
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 23 (1) , 231-238
Abstract
Despite the fact that benefit–risk analysis is a necessary component of the review of new drugs for potential regulatory approval in the presence of known adverse side effects, and of the review of already-approved drugs for possible withdrawal from the market when unanticipated adverse events are discovered, formal quantitative tools for benefit–risk analysis are few. This paper proposes a quantitative method that utilizes receiver operating characteristic (ROC) curves to find an optimal dose of a drug that maximizes the differential between the benefit of the intended effect and the risk of adverse side effects, where costs associated with lack of benefit and risk can be incorporated. The method can be applied separately to subpopulations of different sensitivities and to different adverse events to give a full picture of the trade-offs between the benefit afforded by the drug and the risk it incurs, and potentially to allow the drug to be approved only selectively for specific subpopulations, or at different doses for different subpopulations.Keywords
This publication has 12 references indexed in Scilit:
- The social value of a QALY: raising the bar or barring the raise?BMC Health Services Research, 2011
- Is Premarket Identification of Hepatotoxic Drugs and Sensitive Patients Possible Based on High-Dimensional ‘Omic Data?Personalized Medicine, 2010
- A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More?Drug Information Journal, 2008
- Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit AnalysisHealth Affairs, 2007
- Joint distribution approaches to simultaneously quantifying benefit and riskBMC Medical Research Methodology, 2006
- Multiple‐Testing Strategy for Analyzing cDNA Array Data on Gene ExpressionBiometrics, 2004
- Benefit‐risk analysis: a proposal using quantitative methodsPharmacoepidemiology and Drug Safety, 2003
- Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and PlaceboCNS Spectrums, 2002
- Benefit, risk, and optimization by roc analysis in cancer radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1985
- Optimal treatment levels in cancer therapyCancer, 1972